↓ Skip to main content

Dove Medical Press

Article Metrics

Role of vandetanib in the management of medullary thyroid cancer.

Overview of attention for article published in Biologics: Targets & Therapy, April 2012
Altmetric Badge

Mentioned by

twitter
2 tweeters

Citations

dimensions_citation
17 Dimensions

Readers on

mendeley
38 Mendeley
Title
Role of vandetanib in the management of medullary thyroid cancer.
Published in
Biologics: Targets & Therapy, April 2012
DOI 10.2147/btt.s24220
Pubmed ID
Authors

Brassard M, Rondeau G

Abstract

Traditionally available treatments, like cytotoxic chemotherapy and external-beam radiation therapy, are limited and essentially ineffective for metastatic medullary thyroid carcinoma (MTC). In the last decade, small-molecule tyrosine kinase inhibitors (TKI) have been introduced in the field of thyroid cancer, after having been shown effective in a wide variety of other tumors. This review focuses on vandetanib (ZD6474, Zactima™; AstraZeneca) and its role in the treatment of MTC. Vandetanib is an oral TKI that targets VEGF receptors 2 and 3, RET, and at higher concentrations, the epidermal growth factor (EGF) receptor. This drug has been tested in two important phase II studies which demonstrated that both the 100 and 300 mg/day dosage of vandetanib have antitumor activity on advanced MTC. A phase III trial (ZETA trial) evaluating vandetanib in 331 patients with locally advanced or metastatic MTC showed a significant prolongation of PFS for patients receiving vandetanib compared with placebo. Toxicity surveillance in all studies reported high rates of adverse effects with diarrhea, rash, fatigue and nausea being the most commonly experienced by patients. Vandetanib is currently approved in the United States for unresectable locally advanced or metastatic MTC and has become a new standard of care in this rare and indolent pathology.

Twitter Demographics

The data shown below were collected from the profiles of 2 tweeters who shared this research output. Click here to find out more about how the information was compiled.

Mendeley readers

The data shown below were compiled from readership statistics for 38 Mendeley readers of this research output. Click here to see the associated Mendeley record.

Geographical breakdown

Country Count As %
Netherlands 2 5%
Italy 1 3%
Unknown 35 92%

Demographic breakdown

Readers by professional status Count As %
Researcher 8 21%
Student > Master 7 18%
Professor > Associate Professor 4 11%
Student > Doctoral Student 4 11%
Student > Ph. D. Student 4 11%
Other 9 24%
Unknown 2 5%
Readers by discipline Count As %
Medicine and Dentistry 16 42%
Agricultural and Biological Sciences 6 16%
Biochemistry, Genetics and Molecular Biology 4 11%
Chemistry 2 5%
Economics, Econometrics and Finance 1 3%
Other 4 11%
Unknown 5 13%

Attention Score in Context

This research output has an Altmetric Attention Score of 1. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 14 April 2012.
All research outputs
#3,557,152
of 5,038,248 outputs
Outputs from Biologics: Targets & Therapy
#70
of 125 outputs
Outputs of similar age
#50,999
of 77,697 outputs
Outputs of similar age from Biologics: Targets & Therapy
#8
of 14 outputs
Altmetric has tracked 5,038,248 research outputs across all sources so far. This one is in the 16th percentile – i.e., 16% of other outputs scored the same or lower than it.
So far Altmetric has tracked 125 research outputs from this source. They receive a mean Attention Score of 2.3. This one is in the 28th percentile – i.e., 28% of its peers scored the same or lower than it.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 77,697 tracked outputs that were published within six weeks on either side of this one in any source. This one is in the 17th percentile – i.e., 17% of its contemporaries scored the same or lower than it.
We're also able to compare this research output to 14 others from the same source and published within six weeks on either side of this one. This one is in the 21st percentile – i.e., 21% of its contemporaries scored the same or lower than it.